Unmet Medical Need In Treating Schizophrenia

Dr. Andrew Satlin, Chief Medical Officer at Intra-Cellular Therapies, discusses the unmet medical need for new therapies to treat schizophrenia. He also discusses how the company’s research approach attempts to target the root of the problem – looking inside the cell to better understand how cells interact and communicate, and how those interactions can manifest as disease.

Dr. Satlin joined the Company as Executive Vice President and Chief Medical Officer in November 2017. Dr. Satlin has over 20 years of industry experience in all phases of drug development in multiple therapeutic areas, including neurology and psychiatry, as well as cardiovascular and metabolic disorders. Prior to joining Intra-Cellular Therapies, Dr. Satlin spent 9 years at Eisai, most recently serving as Executive Vice-President, Global Head of Medicine Creation Strategy, Neurology Business Group. Before joining Eisai, he spent 11 years at Novartis in positions of increasing responsibility, including leadership of the Neurosciences regulatory group. Prior to joining Novartis Dr. Satlin was an Assistant Professor of Psychiatry at Harvard Medical School. Dr. Satlin was also the Director of Geriatric Psychiatry and established a dementia clinic at McLean Hospital in Massachusetts. Dr. Satlin received his medical degree from Harvard Medical School and completed his residency in psychiatry and fellowship in geriatric psychiatry at McLean Hospital. Dr. Satlin received his bachelor’s degree from Yale University.